慢性髓性白血病有没有最好的前线治疗方法?
Akriti G Jain1, Mark Dalgetty2, Jorge E Cortes3
1Taussig Cancer Institute, Cleveland Clinic, Cleveland, OH, USA; Cleveland Clinic Lerner College of Medicine, Case Western Reserve University, Cleveland, OH.
Haematologica
|December 11, 2025
概括
在慢性阶段慢性髓性白血病 (CML-CP) 选择氨酸激酶抑制剂 (TKI) 需要个性化治疗. 这些因素包括患者需求,疾病特征和药物特异性结果,以实现最佳的CML-CP管理.
科学领域:
- 血液学 血液学 血液学
- 在瘤学瘤学.
- 药理学 药理学是指药理学的学科.
背景情况:
- 伊马替尼自2001年以来彻底改变了慢性阶段慢性髓性白血病 (CML-CP) 管理.
- 现在已经批准了几种氨酸激酶抑制剂 (TKI),包括第二代TKI (2G-TKI) 和阿西米尼布,用于前线CML-CP治疗.
- 与伊马替尼比相比,2G-TKIs和阿西米尼布显示出更高的分子响应率.
研究的目的:
- 为新诊断的CML-CP患者个性化选择TKI提供指导.
- 突出影响CML-CP管理中TKI选择的关键因素.
主要方法:
- 临床数据的审查和TKIs在CML-CP中的比较疗效.
- 分析影响治疗决策的患者相关,疾病相关和药物相关因素.
- 考虑无治疗缓解 (TFR) 作为治疗目标.
主要成果:
- 对于2G-TKI之间的直接比较,存在有限的前性数据.
- 在伊马替尼和2G-TKI之间,生存结果似乎相似.
- 阿西米尼布在分子反应方面显示出对2G-TKI的潜在优势.
结论:
- 对CML-CP患者来说,个性化的TKI选择至关重要.
- 治疗决策应综合患者因素 (年龄,并发症,生活质量,TFR目标),疾病因素 (风险,突变) 和药物因素 (疗效,安全性,TFR率).
- 共同决策对于优化CML-CP管理至关重要.
相关概念视频
02:50Combination Therapies and Personalized Medicine
5.8K
Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
5.8K
02:57Targeted Cancer Therapies
8.6K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
There are several types of targeted therapies against...
8.6K
01:15Differentiation of Common Myeloid Progenitor Cells
3.9K
Common myeloid progenitors (CMPs) are oligopotent cells that can differentiate into granulocytes and macrophages. Granulocytes and macrophages are essential for protecting the body against bacterial, viral, or fungal infections. They migrate from the bone marrow into the circulating blood to reach specific tissue sites where they differentiate and help in immune surveillance. However, they survive only for a few days and must be continuously made available to the organism to maintain a robust...
3.9K
02:56Treatment Resistant Cancers
3.7K
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
3.7K
01:21Stem Cell Therapy for Tissue Regeneration
4.6K
Stem cell therapy is a method used in regenerative medicine to repair and restore function to damaged tissues and organs. Stem cells have the potential to proliferate and differentiate into various tissue types, making them ideal candidates for tissue regeneration. For example, hematopoietic stem cell transplants are commonly used in blood cancer treatment to replenish damaged bone marrow and restore healthy blood cells.
Types of Stem Cells used in Stem Cell Therapy
The two main cell...
Types of Stem Cells used in Stem Cell Therapy
The two main cell...
4.6K